Aspirin Use in Branch Retinal Vein Occlusion in Diabetic and Hypertensive Patients

Year 2013, Volume: 15 Issue: 2, 35 - 37, 01.07.2013

Murat Tunç Harun Yüksel Elif Önder Murat Kaya Halil İbrahim Onder

Abstract

Purpose: The aim was to investigate whether aspirin use is a risk factor in Branch retinal veinocclusion in hypertensive and diabetic patients.Materials and Methods: The study included 30 hypertensive patients who were diagnosedbranch retinal vein occlusion. Visual acuity, width of retinal hemorrhages, macular edema andretinal neovascularization were compared between aspirin using and non-using patients.Results: Of the 30 cases, 18 were using aspirin, 12 were not. Visual acuity less than 0.1 wasobserved in 10 of 18 aspirin using patients and 3 of 12 non-using patients (p = 0.09). There wasno correlation between visual acuity and wide of retinal hemorrhage.Conclusion: The use of aspirin in patients with well controlled hypertension and diabetes maypositively effect the visual outcome

Keywords

Aspirin, Branch retinal vein occlusion, Hypertension

Retina Ven Dal Tıkanıklığı Geçiren Hipertansif ve Diyabetik Olgularda Aspirin Kullanımı

Abstract

Amaç: Retina ven dal tıkanıklığı (RVDT) geçiren hipertansiyonu ve diyabeti olan olgulardaAspirin kullanımının bir risk faktörü olup olmadığını araştırmak amaçlanmıştır.Gereç ve Yöntem: Çalışmaya RVDT geçiren 30 hipertansif olgu dahil edilmiştir. Bu olgulardanAspirin kullanan ve kullanmayanlar görme düzeyi, retina kanamalarının genişliği, maküla ödemive retinada yeni damar oluşumu yönünden irdelenmiştir.Bulgular: Çalışmaya alınan 30 olgudan 18'i Aspirin kullanmıyordu 12'si ise Aspirinkullanıyordu. Aspirin kullanmayan 18 olgudan 10'unda görme düzeyi 0.1'in altındaydı. Aspirinkullanan 12 olgudan 3'ünde görme 0.1 ve alında saptandı. (p=0.09) Aspirin kullanan olgulardahemoraji yaygınlığı ile görme düzeyi arasında bir korelasyon saptanmadı.Sonuç: Düzgün kan basıncı kontrolü sağlanan diyabetik olgularda Aspirin kullanımı görselprognozu olumlu etkileyebilir

Keywords

Aspirin, Retinal ven dal tıkanıklığı, Hipertansiyon

References

• Rogers S, McIntosh RL, Cheung N, et al. International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313– 319.e1.
• Cheung N, Klein R, Wang JJ, et al Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multi-ethic study of atherosclerosis. Invest Ophthalmol Vis Sci 2008;49:4297–302.
• Sanborn GE. Venous occlusive disease of retina. In: Tasman W, Jaeger E, eds. Duane’s Clinical Ophthalmology. Chapter 15. Philadelphia: Lippincott. Revision; 1996: 3.
• Liesegang TJ, Deutsch TA, Grand MG. Retinal Vascular Disease, in Basic and Clinical Science Course. Section 12; Chapter 5. San Francisco: Foundation of the American Academy of Ophthalmology. 2001 – 2002: 127 – 131.
• Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N Engl J Med 2010;363:2135–2144.
• Turello M, Pasca S, Daminato R, et al. Retinal vein occlusion: evaluation of ‘classic’ and ‘emerging’ risk factors and treatment. J Thromb Thrombolysis 2010; 29:459–464.
• Battaglia Parodi M, Bandello F. Branch retinal vein occlusion: classification and treatment. Ophtalmologica 2009;223:298– 305.
• Wong TY, Larsen EKM, Klein R, et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities and Cardiovascular Health Studies. Ophthalmology 2005;112:540–547.
• Figueroa MS, Torres R, Alvarez MT. Comparative study of vitrectomy with and without vein decompression for branch retinal vein occlusion: a pilot study. Eur J Ophthalmol. 2004; 14: 40 – 47.
• Glacet-Bernard A, Kuhn D, Vine AK, Oubraham H, Coscas G, Soubrane G. Treatment of recent-onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol. 2000; 84: 609 – 613.
• Achenbach LO, Weller-Mann G .Visual outcome after treatment with low-dose taps. Ophthalmologica. 1999; 213: 360 – 366.
• Lahey JM, Fong DS, Kearney J. Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers. 1999; 30: 427 – 434.
• Vannas S, Orma H. Experience of treating retinal venous occlusion with anticoagulant and antisclerosis therapy. Arch Ophthalmol. 1957; 58: 812 – 828.
• The Branch Retinal Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984; 98: 271 – 282.
• Senen K, Topal E, Kilinc E, et al. Plasma viscosity and mean platelet volume in patients undergoing coronary angiography. Clin Hemorheol Microcirc. 2010;44:35–41.
• Leoncini G, Signorello MG, Segantin A, et al. In retinal vein occlusion platelet response to thrombin is increased. Thrombosis Research 2009;124e48–e55.
• Dodson PM, Westwick J, Marks G, Kakkar VV, Galton DJ. Beta-thromboglobulin and platelet factor 4 levels in retinal vein occlusion. Br J Ophthalmol 1983;67:143–146.
• Leoncini G, Bruzzese D, Signorello MG, et al. Platelet activation by collagen is increased in retinal vein occlusion. Thromb Haemost 2007;97:218–227.
• Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J 2001;22:1561-1571.
• Liew G, Mitchell P, Leeder SR, Smith W, Wong TY, Wang JJ. Regular aspirin use and retinal microvascular signs: the Blue Mountains Eye Study. J Hypertens. 2006 Jul;24(7):1329 35.
• Early Treatment Diabetic Retinopathy Study Research Group : Effect of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology, 1991; 98: 757-765.
• The DAMAD Study Group : Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical tral. Diabetes, 1989; 38: 491-498.
• Handin RA, Anticoagulant, fibrinolytic, and antiplatelet therapy. In: Braunward E, Fausi AS, eds. Harrison’s Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001: 758 – 760.
• Harker LA. Antithrombotic therapy. In: Bennet JC, Plum F, eds. Cecil Textbook of Medicine. 21th ed. Philadelphia: Saunders; 2000: 119 – 122.